Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0043320180410100967
Archives of Pharmacal Research
2018 Volume.41 No. 10 p.967 ~ p.976
Aspirin-inspired acetyl-donating HDACs inhibitors
Lim Ji-Ah

Song Yoo-Jin
Jang Jung-Hee
Jeong Chul-Ho
Lee Soo-Yeun
Park Byoung-Duck
Seo Young-Ho
Abstract
Aspirin is one of the oldest drugs for the treatment of inflammation, fever, and pain. It is reported to covalently modify COX-2 enzyme by acetylating a serine amino acid residue. By virtue of aspirin¡¯s acetylating potential, we for the first time developed novel acetyl-donating HDAC inhibitors. In this study, we report the design, synthesis, in silico docking study, and biological evaluation of acetyl-donating HDAC inhibitors. The exposure of MDA-MB-231 cells with compound 4c significantly promotes the acetylation of ¥á-tubulin and histone H3, which are substrates of HDAC6 and HDAC1, respectively. In silico docking simulation also indicates that compound 4c tightly binds to the deep substrate-binding pocket of HDAC6 by coordinating the active zinc ion in a bidentate manner and forming hydrogen bond interactions with Ser531 and His573 amino acid residues. In particular, compound 4c (GI50?=?147 ¥ìM) affords the significant enhancement of anti-proliferative effect on MDA-MB-231 cells, compared with its parent compound 2c (GI50?>?1000 ¥ìM) and acetyl-donating group deficient compound 6 (GI50?=?554 ¥ìM). Overall, compound 4c presents a novel strategy for developing acetyl-donating HDAC inhibitors.
KEYWORD
Aspirin, Histone deacetylases, Cancers, Alzheimer¡¯s disease, Drug addiction
FullTexts / Linksout information
Listed journal information
SCI(E) MEDLINE ÇмúÁøÈïÀç´Ü(KCI)